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to monitor permeabilized zones in the brain, differentiating between 
transiently and permanently permeabilized brain tissue. 
Materials and Methods: Electroporation (EP) was applied in the rat 
brain in vivo (n=48) to induce cell permeabilization ranging from 
transient to permanent (Figure 1). DW-MRI (human 3T MRI system) was 
acquired 5min, 2h, 24h and 48h after EP. The DWIBS sequence (b-
values: 50, 100, 150, 600, 800, 1000 s/mm2) was applied. ADC and 
kurtosis were derived by polynomial fitting to the series expansion of 
the Stejskal-Tanner expression. Electric field calculations were based 
on the finite element method. 
Results: ADC was significantly increased in the transiently 
permeabilized brain tissue (pooled: P<0.01, 2h: p<0.04), and in the 
more severely permeabilized brain tissue (24h: p<0.03). ADC increase 
in the permanently permeabilized tissue was delayed. Kurtosis was 
increased in both the transiently and permanently permeabilized brain 
tissue (pooled: P<0.01, P<0.02, P<0.00003). Histology showed 
correlation to the ADC and kurtosis changes. Overlay of calculated 
electric field contour on histology samples (Figure 1) confirmed 
transient permeabilization (edema at 300-600 V/cm) and permanent 
permeabilization (lysis and necrosis at 1000-1200 V/cm). 
 
  
Figure 1 Representative histological samples and DW-MRI images of 
both transiently (24h) and permanently permeabilized (48h) zones in 
the brain. The dashed lines show the correspondence between the 
planes. The dashed boxes show the selected regions of interest (ROI).  
Conclusions: Results indicate that DW-MRI is capable of defining 
permeabilized zones in the rat brain, and specifically to differentiate 
between transiently and permanently permeabilized tissues. This 
suggests that DW-MRI may potentially be used for early verification of 
radiation dose delivery to target. Further, DW-MRI may serve as a 
biomarker predicting treatment outcome, based on the severity of 
membrane permeabilization seen immediately after irradiation.  
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Purpose/Objective: In head and neck cancer (HNC) the ability to 
anticipate an individual patient's outcome is very valuable. Diffusion 
weighted MRI (DWI) can characterize the tumor's microstructure and 
might prove a valuable asset in response prediction. With this study 
we wanted to investigate the predictive value of pretreatment ADC 
values in a large patient population and investigate the clinical value 
of such a predictive model. 
Materials and Methods: Between August 2004 and May 2010 161 
patients with pathology proven HNC were included in this study. All 
patients underwent a pretreatment MRI with DWI using six b-values 
(0,50,100,500, 750 and 1000s/mm²). For each tumor, two ADC values 
were calculated using different b-values: ADClow (b:0-50-100s/mm² 
and ADChigh (b500-750-1000s/mm²). The clinical variables included: 
tumor and nodal volume, tumor location and age. Three year disease 
free survival (DFS), locoregionalcontrol (LRC) and distant metastasis 
free survival (DM) were determined using a Kaplan-meier estimate. 
Variables were incorporated into a multivariate competing risk 
analysis for DFS, LRC and DM. The prediction model for DFS was 
validated using the Harrell's c-statistic and by dividing patients in 
three groups based on prognosis. This information was then distilled 
into a nomogram correlating clinical and imaging parameters with 
DFS.  
Results: Median follow-up was 50 months (range 4-86). Atotal of 67 
patients experienced disease recurrence during follow-up (42%).Three 
year DFS, LRC and DM were 60%, 70%and 78% respectively. After 
multivariate analysis tumor volume, nodal volume and ADChigh were 
shown to be significant and independent predictors for DFS. ADChigh 
predicted LRC more strongly, while tumor and nodal volume seemed 
to be more predictive of DM (Table 1.) The Harrell's c-index for the 
prediction model for DFS was 0.62 (0.55-0.96 95% CI). After bootstrap-
based validation the group with the worst prognosis had a DFS 
probability of 44% after 3 years. The remaining two patient groups had 
a DFS probability of 67% and 69% respectively. All parameters were 
put into a nomogram predicting DFS probability (Figure 1). 
 
 
 
 
Conclusions: The pretreatment ADCvalue, derived from high b-values, 
appears to be a strong predictive factor in HNC patients treated with 
radiotherapy. The construction of a predictive model based on the 
combination of functional imaging and clinical parameters might be a 
helpful tool in the process of treatment selection. Adding biological 
and molecular parameters to such a model might further increase its 
performance.  
   
OC-0325   
Pre-Radiotherapy 18Fluoromisonidazole PET Predicts for Long 
Term Local Control and Survival in Head and Neck Cancer 
J. Jackson1, M. Wada1, S.T. Lee2, H. Gan3, A. Poon2, S. Gong2, D. 
Gunawardana2, D.L. Joon1, P. Khaw1, A.M. Scott2 
1Austin Olivia Newton John Cancer and Wellness Centre, Radiation 
Oncology, Heidelberg, Australia  
2Austin PET Centre, Nuclear Medicine, Heidelberg, Australia  
3Austin Olivia Newton John Cancer and Wellness Centre, Medical 
Oncology, Heidelberg, Australia  
 
Purpose/Objective: To evaluate the utility of 18Fluoromisonidazole 
(FMISO) Positron Emission Tomography (PET) scans performed prior to, 
during and following curative intent radiotherapy (RT) for head and 
neck cancer. 
Materials and Methods: Eighteen prospectively accrued patients (50% 
with oropharyngeal primaries) underwent FMISO PET scans prior to 
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definitive RT, with or without concurrent chemotherapy, for head and 
neck cancer. Sixteen patients had FMISO PET scans in week 3 of RT 
and 14 completed a third scan upon completion of therapy. Maximum 
standard uptake values (SUVmax) and tumour-to-normal ratios (TNR) on 
the FMISO PET scans were measured as indictors of hypoxia. All 
patients underwent an 18Fluorodeoxyglucose (FDG) PET prior to 
commencing therapy and 14 had an FDG PET at 12 weeks post 
completion of RT. Median follow-up was 62 months with a minimum of 
58 months in surviving patients. 
Results: Twenty-seven FMISO avid lesions were detected. No local 
failures were observed in 14 lesions with an FMISO TNR 1.3 (61.5% vs. 
100%, p = 0.016). Overall survival (OS) at 5 years was poorer in 
patients with a FMISO TNR lesion of >1.3 (27.3% vs. 100%, p = 0.004) 
and a trend towards worse disease specific survival (DSS) (63.6% vs. 
100%, p = 0.12) was observed in this group. Complete resolution of 
FMISO uptake was seen in 14 patients, with 85% resolving before 
receiving 30 Gy. This was not associated with improved LC, DSS or OS 
nor was complete metabolic response on FDG PET, which occurred in 
71.4% of patients. FMISO SUVmax was not significantly associated with 
patient outcomes. 
Conclusions: Pre-radiotherapy FMISO PET is predictive for poor 
patient outcomes at 5 years, despite apparent disease response on 
serial functional imaging. FMISO PET has the potential utility for risk 
stratification and also provides valuable spatial information regarding 
patterns of failure and warrants further clinical evaluation. 
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Purpose/Objective: Tumour hypoxia hampers the efficacy of 
radiotherapy (RT) due to increased radioresistance. Tumour hypoxia 
can be visualized by PET using hypoxia tracers like 18F-FAZA. However, 
previous studies showed that high 18F-FDG uptake is also associated 
with hypoxia. In this respect, the question arises as to whether 18F-
FDG and 18F-FAZA uptake show high spatial correlation or provide 
complimentary information that can be used for RT treatment 
optimization strategies. Therefore, the aim of the present study was: 
(1) to quantify tumour hypoxia using 18F-FAZA-PET,and: (2) to 
investigate the spatial 18F-FAZA-uptake in relation to 18F-FDG-uptake. 
Materials and Methods: Eleven patients with stage III or IV NSCLC 
underwent 18F-FDG and 18F-FAZA-PETprior to chemo(radio)therapy. To 
depict 18F-FDG uptake, the maximum standardized uptake value 
(SUVmax) was used, whereas to quantify hypoxia, the tumor-to-
background ratio (T/B ratio) was used and the percentage of tumour 
exhibiting a fractional hypoxic volume (FHV) > 1.4 was assessed. Both 
PET scans were made in treatment position. To enable spatial 
correlation between 18F-FDG and 18F-FAZA scans, voxel based analysis 
of respective uptake values employing deformable image registration 
was performed. 
Results: All eleven patients showed clear uptake of 18F-FAZA in the 
primary tumour. No significant correlation was observed between 18F-
FDG-SUVmax and the 18F-FAZA-T/B ratio. The median FHV 1.4 was 
48.4% (range5.0-91.5). Neither lesion size nor 18F-FDG SUVmax 
significantly correlated with FHV, whereas a significant correlation 
between 18F-FDGSUVmax and lesion size (r = 0.82; P = 0.002) was 
observed. The pattern of uptake of 18F-FAZA varied widely among 
tumours and was more heterogeneous compared to uptake of 18F-FDG, 
resulting in different spatial distribution patterns (Fig 1). Inmost 
patients, there was a trend towards higher 18F-FAZA-uptake with 
increasing uptake of 18F-FDG. In some patients (panel A), well 
demarcated high uptake areas of 18F-FAZA were observed within 
metabolically active tumour volumes, indicating local hypoxic 
subareas in tumours with high metabolic activity. In other patients, 
18F-FAZA and 18F-FDG were more diffuse and did not correlate at all 
(panel B), indicating a more heterogeneous distribution of hypoxia 
throughout the entire tumour. 
 
Conclusions: 18F-FDG and 18F-FAZA-PETdata provide independent 
information about tumor metabolism. Addition of 18F-FAZA-PET to 18F-
FDG-PET imaging may direct the choice of hypoxia-directed RT 
treatment planning in NSCLC. 
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Purpose/Objective: FDG based metrics of the primary tumor at 
baseline PET images have been found predictive for overall survival in 
NSCLC patients. In this study the predictive power of advanced 
metabolic metrics derived from baseline PET images were compared 
against those already widely used, as maximum and mean uptake, and 
GTV. With this approach we aim to improve the existing predictors of 
outcome, allowing the implementation of decision support-based 
individualized care systems (www.predictcancer.org). 
Materials and Methods: In the context of a prospective study 
(NCT01302626), 197 NSCLC patients, stages I-III, treated with curative 
intent were included. Each patient underwent a precalibrated PET-CT 
scan before radiotherapy treatment. Primary GTV was delineated on 
CT by an experienced oncologist. PET images were normalized for SUV 
prior to analysis. We derived mean and maximum SUV, GTV and a set 
of metabolic features, quantified by an Intensity-Volume Histogram 
that summarizes into a single curve the spatial relation of tumor 
volume and SUV (Figure1): 
- Absolute/RelativeVolume above Absolute Intensity threshold – AVAI 
and RVAI 
- Absolute/RelativeVolume above Relative Intensity threshold – AVRI 
and RVRI 
- AbsoluteIntensity above Relative Volume threshold – AIRV 
AVAI and RVAI are built in steps of 0.5 (SUV) up to the maximum 
uptake (Figure 1B). Curves regarding relative quantities are built in 
steps of 10% (Figure 1 A and C). 
A Cox Proportional Hazard Regression was performed for overall 
survival. Performance was evaluated by the Concordance Index 
(probability of concordance between predicted and observed survival 
based on pairs of individuals: C-index). The proportional hazards 
assumption was checked by the Scaled Schoenfeld residuals by 
entering interaction terms with (log)time in the model. All statistical 
methods were applied with R (version 2.15.0). 
 
 
